🏛️ Missouri Routes Hemp Through Dispensaries, Medicare CBD Pilot Goes Live, and Massachusetts Social Equity Operators Fight Back

Built by a former cannabis regulator, Policy, Decoded helps operators read the policy terrain before it shifts beneath their feet.

Today's edition is sponsored by The Current. Their support keeps these briefings free and focused on what actually matters.

There is a version of cannabis policy where every branch of government moves at the same speed toward the same destination. That version does not exist. Today's edition tracks what happens instead: Missouri uses a federal rewrite as a consolidation tool to route hemp products through dispensaries. A federal judge lets the Medicare CBD pilot launch over SAM's objections. Social equity operators in Massachusetts go to court to stop a repeal ballot question funded entirely by a national prohibitionist group. And the White House invites stakeholders into a room to talk about CBD enforcement policy without actually telling anyone what that policy is. The system is running multiple tracks at once, and the people absorbing the risk are the ones who have to guess which tracks converge.

🏛️ Missouri locks hemp into the dispensary lane
💊 Medicare CBD pilot survives its first legal test
⚖️ Massachusetts social equity operators fight for their businesses

Four cannabis business owners filed suit in Massachusetts Supreme Judicial Court to block the SAM-backed ballot question that would repeal the state's adult-use legalization law. The plaintiffs are Caroline Pineau of Stem Haverhill, Gyasi Sellers of Treevit LLC, and Lisa Mauriello and Boey Bertold of Paper 4 Crane Provisions. All four are recipients of Social Equity Trust Fund grants, and all four are well-regarded operators who built their businesses within the framework the state created to make this industry look different from the ones that came before it. Their complaint names Attorney General Andrea Campbell and Secretary of State William Galvin and argues the ballot question unconstitutionally bundles unrelated provisions, violating the state's single-subject requirement. The legal theory is a longshot. The tactic is not. By putting local faces and real businesses in front of the press, these plaintiffs are reminding Massachusetts voters what a yes vote on this question actually destroys: the very businesses the state spent years building programs to support. The Coalition for a Healthy Massachusetts, which is behind the initiative, received $1.55 million solely from SAM Action Inc. to fund its signature drive. SAM's prohibitionist project is well-funded and disciplined, and it should be taken seriously. No state has ever reversed a voter-approved legalization law, and Massachusetts's $1.6 billion annual market, $900 million in excise tax revenue, and roughly 27,000 jobs sit in the balance. The Legislature has until May 5th to act on the petition. If it does not, organizers must collect another 12,429 signatures by July 1st to reach the November ballot. (The Boston Globe)

The U.S. Tax Court upheld the IRS's rejection of Mission Organic Center Inc.'s offer in compromise, backing the agency's policy of excluding marijuana business expenses barred by Section 280E when calculating reasonable collection potential. That formula turned a San Francisco dispensary's collectible amount into a paper figure of roughly $57.9 million against a tax liability of about $5.25 million. The court drew a distinction that matters: Section 280E itself does not dictate the collection formula, but the IRS is allowed to adopt that policy through its internal collection rules. That gives the IRS room to weaponize federal illegality twice, once on the assessment side and again on the collection side. The timing adds a layer. Rescheduling lingers in the background, and plenty of operators are planning for a future where 280E falls away. That future has not arrived. Companies still have tax obligations under the current federal framework, and the IRS is not waiting for Congress or DEA to sort out what comes next. For plant-touching operators carrying tax debt, compromise relief just got harder to reach. A good CFO and accounting firm are worth their weight in cannabis right now. (The Tax Adviser)

The New Jersey Cannabis Regulatory Commission used its March 31st meeting to mark a real transition, with Chair Dianna Houenou saying it was her last public board meeting as Commissioner Jackie Ferraro joined the panel. The Commission also approved the Blazin Buddiez cannabis consumption lounge in Millville. I got to know Dianna through CANNRA and on the speaking circuit, and I admire the work she and the team in New Jersey have done with their rollout. She was a sincere public servant. The question now is whether the next Commission treats implementation as routine expansion or as a tighter political balancing act. Lounge approvals are no longer novelty items. They are unfolding during a live handoff in institutional leadership, which means pace, tone, and enforcement priorities may start shifting at the same time the market is testing a new retail format. (National Today; Heady NJ)

🏙️ Buchanan Mayor Mark Weedon is making an argument more local officials should confront: cannabis businesses can function as ordinary parts of a downtown economy. Dispensaries and processors brought foot traffic, jobs, and spillover spending without the crime wave critics warned about. The pressure point now sits higher up. Weedon says Michigan's 24 percent wholesale tax is squeezing operators and leaving municipalities with too little of the revenue generated in their own towns. Local acceptance is growing, but state tax policy may end up doing the damage local opposition failed to do. (WSJM)

Kentucky hemp farmers are making crop decisions under a federal cloud, with planting season here and no clear fix for the 2025 federal rewrite that narrows the definition of legal hemp. Industry and state voices, including Agriculture Commissioner Jonathan Shell, have pushed for a two-year delay through the Hemp Planting Predictability Act, backed by Reps. Jim Baird and James Comer. Farmers were always going to be the early domino in hemp's yearlong plank walk. Seeds go in the ground in May, and the decisions being made right now around financing, labor contracts, and acreage will determine the ingredient supply chain for the rest of the industry. Whether Kentucky farmers plant this crop, and how much of it, will ripple through processors, manufacturers, and beverage companies that depend on a steady, legal hemp supply. The consumables sector is watching closely. Washington changed the rules on paper, then left growers to absorb the commercial risk in real time. Kentucky knows this crop, and that is exactly why the uncertainty cuts so deep. (FOX 56 News; LPM)

After a seven-hour filibuster by State Sen. Karla May and a separate hour-long delay by Sen. Mike Moon, the Missouri Senate advanced legislation that would ban most intoxicating hemp products outside the state's licensed marijuana dispensaries and cap hemp products at 0.4 milligrams of THC per container. May, who had blocked an earlier version sponsored by Sen. David Gregory that would have taken effect immediately, negotiated an amendment setting the effective date at November 12th. She agreed to end the filibuster and let the Hinman bill come to a vote. The measure goes beyond federal mirroring. It reclassifies hemp-derived cannabinoids as marijuana, routing most surviving products through dispensaries even if Congress later loosens course. Hemp businesses say they were shut out of the final negotiations, with hemp business owner John Grady saying marijuana lobbyists dominated the hallway during the debate. That tracks with a broader pattern. Anheuser-Busch InBev has been lobbying Congress on hemp differentiation from beer, and Steven Busch of Krey Distributing, a member of the Busch family who has distributed hemp beverages across eastern Missouri, has been a vocal advocate for regulation over prohibition. The beer industry is genuinely infatuated with hemp beverages, but AB InBev also knows it is the bully in the room, and in Missouri, that room is home turf. Missouri is showing how the federal rewrite can become a state-level consolidation tool, shifting shelf space, compliance burden, and customer access toward the licensed cannabis system. (Missouri Independent)

🌿 Canadian firms are already organizing around the CMS pilot as a commercial opening. High Tide's NuLeaf Naturals is moving to engage participating organizations and Tilray has signaled interest. Even a narrow federal reimbursement pathway is enough to attract cross-border attention from scaled cannabinoid companies that see medical credibility and market access moving in the same direction. Once outside companies start organizing around a pilot, it stops looking temporary and starts looking like a foothold. (StratCann)

A federal judge denied Smart Approaches to Marijuana's request for a temporary restraining order, and the Centers for Medicare and Medicaid Services' CBD pilot program launched yesterday. The program lets participating organizations consult eligible Medicare beneficiaries about hemp-derived CBD products and provide up to $500 per year in covered products, with oral products capped at 0.3% delta-9 THC and 3 milligrams of total THC per serving. Judge Trevor McFadden did not bless the program on the merits. He found SAM had not cleared the high bar for emergency relief and set an April 20th hearing on the next round of injunction requests. SAM is well-funded and persistent, and the April 20th hearing will be a fuller test of whether this program can survive legal challenge. The practical consequence is immediate all the same: access has begun, and any challenge now has to unwind a live federal pilot instead of stopping one before launch. Dr. Mehmet Oz formally announced the program, structuring it with dosage and product-type guardrails. Once federal healthcare dollars begin flowing into cannabinoid products, even through a pilot, the conversation shifts from permissibility to standardization. That pulls in scheduling, clinical validation, and regulatory oversight all at once. (Cannabis Business Times; Marijuana Moment)

The White House held its first stakeholder meeting on a pending federal CBD enforcement policy, with OIRA and FDA officials listening to industry input while refusing to say what the policy is or when it will be released. Here is what the meeting actually tells you: the White House is still figuring out its path forward between the hemp ban, the CMS pilot, rescheduling, and whatever the FDA decides it wants to do about CBD. Cannabis as a plant is governed by a sprawl of federal bureaucracy whose missions are not always aligned. DEA cares about scheduling. FDA cares about product safety and drug approval pathways. CMS just launched a reimbursement pilot. USDA still oversees hemp cultivation. And OIRA is trying to coordinate a policy that touches all of them without any of them having agreed on where the lines fall. The risk is not delay alone. It is that federal agencies are building adjacent cannabis and hemp policy tracks without showing the market how those tracks fit together. Businesses are left reading tea leaves around enforcement, reimbursement, and product definitions simultaneously, which is not a policy environment. It is a guessing game with real capital at stake. (Marijuana Moment)

Beyond Pesticides is using a new contamination study to press a familiar point: cannabis sits in a federal pesticide gray zone where cultivation is widespread, consumer exposure is real, and the core federal registration system still does not apply. FIFRA leaves states improvising their own allowed-use lists, testing protocols, and enforcement approaches, producing a patchwork with obvious holes. What makes this particularly urgent is the range of ingestion methods involved. Cannabis consumers are not just eating a product off a shelf. They are combusting flower, applying topicals, taking tinctures sublingually, consuming edibles, and in some cases using suppositories. Each of those delivery methods carries a different exposure profile for pesticide residue, and none of them map neatly onto the food-safety frameworks that federal registration was designed to address. States can legalize sales and stand up testing programs, but they cannot fully solve a crop-protection framework that depends on federal registration and label law. (Beyond Pesticides)

Cornbread Hemp has launched THC beverages in Kentucky, adding another home-state entrant to a category growing fast on unstable legal footing. Cornbread has not been quiet about the stakes. Co-founder Jim Higdon hosted Sen. Rand Paul at the company's Louisville facility ribbon cutting in December, where Paul blasted the McConnell-authored hemp ban and called it an existential threat to a Kentucky-grown industry. The company also just secured an exclusive supplier contract with Alliant Purchasing for the CMS Medicare CBD pilot, covering 68,000 healthcare provider locations. Cornbread maintains working relationships with every member of the Kentucky congressional delegation, and Higdon was elected to chair the U.S. Hemp Roundtable in 2026. This is a company that is building commercial infrastructure and political capital at the same time, betting that if low-dose beverages survive the policy fight, early brands own mindshare. The risk is just as clear. They are investing in a market that lawmakers still have not finished defining. (Courier Journal; Lane Report; LPM)

🥤 Julie Rhodes and the Kick Fizz team earned a real milestone: Best CBD-THC Beverage at the 2026 WSWA Wine & Spirits Tasting Competition. Food & Wine's coverage matters beyond the brand win. WSWA's event puts hemp drinks in front of the wholesale and retail gatekeepers who still decide whether this category gets treated as novelty or a real beverage business. Kick Fizz won with a low-dose 1:1 formula, priced at $14 for a four-pack, reinforcing where the scalable part of the market appears headed: approachable dose, familiar format, cleaner shelf logic. (Food & Wine)

Minnesota's Office of Cannabis Management began accepting applications on April 1st for lower-potency hemp edible retailer, manufacturer, and wholesaler licenses. The reopening follows roughly 3,500 applications processed over the previous five months, with more than 1,500 licensed hemp-derived THC businesses already operating in the state. Executive Director Eric Taubel framed the window against the November 2026 federal ban, noting that businesses in the low-potency hemp space often depend on federal legality for interstate commerce, banking, and supply chain stability. The state also recently signed a bill allowing out-of-state lab testing through May 2027 to ease testing capacity pressure. Minnesota is calibrating in real time: inviting more participation in the compliant, low-dose lane while acknowledging the federal clock. (FOX 9 News; Red Lake Nation News)

🏛️ Nebraska lawmakers passed LB 1235 by a 46-2 vote, funding the state's new Medical Cannabis Commission and sending about $2.38 million across two fiscal years to stand up the regulatory operation. The Legislature stripped out broader authority over patients and providers, keeping this closer to a startup package than a policy rewrite. Voters legalized access in 2024. Now the state is finally paying for the machinery. (Marijuana Moment; Nebraska Examiner)

A Florida federal judge ruled that Berkshire Hathaway Homestate Insurance must defend Trulieve in the wrongful death suit tied to Lorna McMurrey's 2022 death at the company's Massachusetts facility. Before anything else, it is worth pausing on the human cost at the center of this case. A worker died, and her family is still seeking accountability. The insurance ruling is a procedural development in a case that carries real grief. Judge Allen Winsor found that the underlying allegations were sufficient to trigger employer's liability coverage, giving Trulieve a procedural win in litigation that has already produced regulatory penalties and reputational damage. Cannabis companies often discover at the worst possible moment that their corporate structure, policy language, and operational risk do not line up once a serious workplace case lands in court. Insurance coverage is governance, not back-office paperwork. When coverage holds, it buys time and leverage. When it fails, every underlying risk gets more expensive at once. (Law360; MJBizDaily; Ganjapreneur)

🌍 Costa Rica completed its first medicinal cannabis shipment to Europe on March 13th, with Hybrida Farms in Cartago meeting EU Good Agricultural and Harvesting Practices standards. The country may have found a more durable near-term lane in exports than in domestic access, where purchases are still limited to locally prescribed products through pharmacies. (Q Costa Rica)